相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R. A. Sooy et al.
ANNALS OF ONCOLOGY (2022)
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang et al.
CANCER RESEARCH AND TREATMENT (2022)
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Yosuke Kawashima et al.
LANCET RESPIRATORY MEDICINE (2022)
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
Jianling Bi et al.
PHARMACEUTICALS (2021)
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Chin-Chou Wang et al.
ONCOLOGY AND THERAPY (2021)
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
Hiroaki Akamatsu et al.
JAMA ONCOLOGY (2021)
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients: A meta-analysis
Nobuaki Kobayashi et al.
THORACIC CANCER (2021)
Toward personalized treatment approaches for non-small-cell lung cancer
Meina Wang et al.
NATURE MEDICINE (2021)
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
Teng Li et al.
THORACIC CANCER (2021)
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Survival of chemo-naive patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
Takashi Ninomiya et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
Svenja Wagener-Ryczek et al.
BMC CANCER (2020)
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
Ping-Chih Hsu et al.
PHARMACEUTICALS (2020)
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Nitin Roper et al.
CELL REPORTS MEDICINE (2020)
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
Ping-Chih Hsu et al.
BIOMEDICINES (2020)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC
Jacek Rutkowski et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study
Shafei Wu et al.
THORACIC CANCER (2019)
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Thomas E. Stinchcombe et al.
JAMA ONCOLOGY (2019)
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol
Takashi Ninomiya et al.
CLINICAL LUNG CANCER (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma
Po-Hao Feng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
Takashi Seto et al.
ONCOLOGY AND THERAPY (2018)
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review)
Kaidi Li et al.
ONCOLOGY REPORTS (2017)
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell et al.
LANCET RESPIRATORY MEDICINE (2017)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C. Zhou et al.
ANNALS OF ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
Sang Yun Ha et al.
Oncotarget (2015)
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
Luis Paz-Ares et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto et al.
LANCET ONCOLOGY (2014)
Study finds different efficacy for afatinib in non-small-cell lung cancer cases with EGF receptor mutations
[Anonymous]
LUNG CANCER MANAGEMENT (2013)
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial
Tony S. K. Mok et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2011)
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan
Myung-Ju Ahn et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
George N. Naumov et al.
CLINICAL CANCER RESEARCH (2009)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
分享论文
